Gout is a chronic inflammatory disease burdened by a higher CV risk compared to the general population [1] and this excess risk cannot be explained only by the prevalence of traditional risk factors. In fact, on top of metabolic risk factors, also including high levels of uric acid, the persistent inflammatory status is instrumental in determining this increased risk. Colchicine (COL) is widely used in rheumatology for treatment and prophylaxis of acute gout flares, other crystal diseases, and autoinflammatory diseases [2,3] and two retrospective cohort studies showed a lower incidence of combined CV outcomes in patients with gout treated with COL [4,5].
